Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Just as expected

<< Previous

Bullboard Posts

Next >>

Comment by Actuarialon Dec 16, 2020 11:27am

113 Views

Post# 32118677

RE:RE:RE:Just as expected

Just grab 1.5k more shares at 3.55. Will buy more if it goes down to that level again.

Straylight wrote: I'm waiting for more room in my TFSA in Jan. as well. Did pick more share up today at $3.61 though so pretty pleased with that. Very much looking forward to January, as others have mentioned I feel like a gradual rise over the first quarter is likely with more excitement later in the year once we move toward the start of phase 3 or a partnering opportunity is announced.

Fireside chat was certainly insightful though I only managed to listen to about an hour of it. More listening for over the holidays I suppose!

<< Previous

Bullboard Posts

Next >>

From now on, dynaCERT instead of Bitcoin or NVIDIA?